EUVIMEDEUVIMED entdecken
FallberichtOpen Access

SLC6A1 G443D associated with developmental delay and epilepsy

Seth Devries, Monica Mulder, Jacob G Charron, Jeremy W Prokop, Paul R Mark

Molecular Case Studies · 2020-08 · 6 (4) · a005371

DOI: 10.1101/mcs.a005371 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Molecular Case Studies, online erschienen am 13.07.2020. Verfasst von Seth Devries und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Neurology, Helen DeVos Children's Hospital, Grand Rapids, Michigan 49503, USA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SLC6A1 is associated with an autosomal dominant early-onset seizure and epileptic encephalopathy associated with intellectual disability. We present a 2-yr-old girl with developmental delay and epilepsy, using a new computational filtering impact score to show the patient's variant ranks with other pathogenic variants. Genomic studies within the patient revealed a G443D variant of uncertain significance. Structural and evolutionary assessments establish this variant as a loss of function to the protein. Compiled metrics through our custom tools on sequence, structure, and protein dynamics combined with PolyPhen-2, PROVEAN, SIFT, and Align-GVGD reveal this variant to rank in the top functional outcome changes relative to gnomAD, TOPMed, and ClinVar variants known to date. The patient was resistant to multiple epileptic drugs, finally finding that valproic acid controls the seizures. This is consistent with additional groups studying SLC6A1 variants within patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Child, PreschoolDevelopmental DisabilitiesEpilepsyFemaleGABA Plasma Membrane Transport ProteinsGenetic Predisposition to DiseaseHumansIntellectual DisabilityLoss of Function MutationMutationPhenotypeSeizuresValproic Acid

Stichwörter der Autor:innen

absence seizuresautismmoderate global developmental delay

Substanzen

GABA Plasma Membrane Transport ProteinsSLC6A1 protein, humanValproic Acid

Autor:innen und Institutionen

  • Pediatric Neurology, Helen DeVos Children's Hospital, Grand Rapids, Michigan 49503, USA.
  • Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, Michigan 49503, USA.
  • Department of Pharmacology and Toxicology, Michigan State University, East Lansing Michigan 48824, USA.
  • Spectrum Health Division of Medical Genetics, Grand Rapids, Michigan 49503, USA.

Förderung

  • NIEHS NIH HHS

Zitieren

APA

Devries, S., Mulder, M., Charron, J. G., Prokop, J. W., & Mark, P. R. (2020). SLC6A1 G443D associated with developmental delay and epilepsy. Molecular Case Studies, 6(4), a005371. https://doi.org/10.1101/mcs.a005371

Vancouver

Devries S, Mulder M, Charron JG, Prokop JW, Mark PR. SLC6A1 G443D associated with developmental delay and epilepsy. Molecular Case Studies. 2020;6(4):a005371. doi:10.1101/mcs.a005371

BibTeX
@article{Devries2020,
  author = {Devries, Seth and Mulder, Monica and Charron, Jacob G and Prokop, Jeremy W and Mark, Paul R},
  title = {SLC6A1 G443D associated with developmental delay and epilepsy},
  journal = {Molecular Case Studies},
  year = {2020},
  volume = {6},
  number = {4},
  pages = {a005371},
  doi = {10.1101/mcs.a005371}
}
Kostenlos starten →